NCT06047028 is a clinical trial in Coronary Artery Disease, sponsored by University of Texas Southwestern Medical Center.

Who is sponsoring NCT06047028?

NCT06047028 is sponsored by University of Texas Southwestern Medical Center.

What condition does NCT06047028 study?

NCT06047028 studies Coronary Artery Disease, Ischemic Heart Disease (IHD), Myocardial Viability.

Is NCT06047028 still recruiting?

NCT06047028 is currently recruiting now. Last updated 27 February 2026.

Last reviewed 2026-02-27 · How we verify

NCT06047028

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Prognostic Value of Hyperpolarized 13C MRI for Clinical Myocardial Viability

Recruiting now Last updated 27 February 2026

What this trial tests

trial in Coronary Artery Disease in 30 participants. Currently enrolling.

Timeline

30 June 2023

Primary endpoint
30 June 2026

30 June 2026

Quick facts

Lead sponsor	University of Texas Southwestern Medical Center
Status	Recruiting now
Study type	OBSERVATIONAL
Enrollment	30
Start date	30 June 2023
Primary completion	30 June 2026
Estimated completion	30 June 2026
Sites	1 location across United States

Conditions studied

Coronary Artery Disease — all drugs for Coronary Artery Disease →
Ischemic Heart Disease (IHD) — all drugs for Ischemic Heart Disease (IHD) →
Myocardial Viability — all drugs for Myocardial Viability →

Sponsor

University of Texas Southwestern Medical Center

Who can join

Adults 20 to 80, any sex, with Coronary Artery Disease or Ischemic Heart Disease (IHD). Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Heart failure due to coronary artery disease represents a significant cause of mortality. The detection of patients eligible for bypass surgery is a pivotal concern. Nevertheless, the optimal approach for patient selection based on conventional imaging scans remains unclear. The proposed method (Hyperpolarized 13C MRI) has gained extensive use in evaluating in vivo metabolism. This method avoids ionizing radiation and provides critical insights into cardiac function. The feasibility study aims to investigate this method for patient selection before bypass surgery. This innovative imaging technique facilitates the identification of two simple molecules, bicarbonate and lactic acid, produced at high rates by normal heart metabolism. Both bicarbonate and lactate originate from the same precursor molecule, pyruvate. The data generated from this study holds the potential to refine diagnostic precision.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

MRI Application and Challenges of Hyperpolarized Carbon-13 Pyruvate in Translational and Clinical Cardiovascular Studies: A Literature Review.
Frijia F, Flori A, Giovannetti G, Barison A, et al · · 2024 · cited 3× · PMID 38786333 · DOI 10.3390/diagnostics14101035
Myocardial Pyruvate Metabolism Before and After CABG in Three-Vessel Disease Using Hyperpolarized Carbon-13 MRI
· 2026

Verify or expand the search:

Other recruiting trials for Coronary Artery Disease

Currently open trials in the same condition.

NCT07399002 — LONG NAGOMI™ PMCF STUDY · recruiting
NCT07420582 — Antegrade Autologous Blood Reinfusion After CPB · recruiting
NCT07493603 — A Study on Yiyang Huoluo Decoction in the Treatment of Coronary Heart Disease · Phase 1, PHASE2 · recruiting
NCT06535568 — Single vs. Dual Antiplatelet Therapy in Elderly or HBR Patients Undergoing Percutaneous Intervention With DCB (PICCOLETO · NA · recruiting
NCT07286578 — A Prospective, Multicenter, Randomized Controlled Trial to Investigate the Value of Coronary CT Angiography in the Under · NA · recruiting

Other University of Texas Southwestern Medical Center trials

Trials by the same sponsor.

NCT03849963 — Imaging Oxidative Metabolism and Neurotransmitter Synthesis in the Human Brain · recruiting
NCT06917183 — Developing Strategies for Implementation and Use of the Operating Room Black Box (ORBB) · NA · not yet recruiting
NCT05145309 — Value of Potassium Magnesium Citrate in Preventing and Treating Hypertension in African Americans · Phase 2 · not yet recruiting
NCT06552000 — Pre-operative Tumor Treating Fields in Patients With Resectable Lung Cancer · NA · not yet recruiting
NCT07387666 — Imaging Acetadote Metabolism in Glioblastoma · EARLY_PHASE1 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06047028 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Texas Southwestern Medical Center
Last refreshed: 27 February 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06047028.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing